Antengene’s ATG-022 clinical study achieves positive results, CR achieved in elderly gastric cancer patient

CAR-T Digest - August 2020

08 August 2025: Antengene’s ATG-022 clinical study achieves positive results, CR achieved in elderly gastric cancer patient

In Antengene’s Phase 1/2 CLINCH study, its in-house CLDN18.2-targeting ADC ATG-022 achieved a CR in an elderly advanced gastric cancer patient who had failed multiple prior therapies
ATG-022 showed broad efficacy across CLDN18.2 expression levels, with ORR/DCR of 42.9%/95.2% in moderate-to-high expression and 30%/50% in low expression patients
The ADC demonstrated a clinically meaningful efficacy and favorable safety profile, suggesting benefit even in ultra-low CLDN18.2 expression cases.
To date, three CR have been observed in the ongoing study, including patients from China and Australia; the Phase 2 dose-expansion is underway in both regions
Updated ATG-022 clinical data will be presented at ESMO 2025, with Antengene aiming for first-in-class and best-in-class positioning for CLDN18.2-positive cancers